1832 Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-4,630
| Closed | -$2.17M | – | 919 |
|
|
2024
Q2 | $2.17M | Sell |
4,630
-1,150
| -20% | -$499K | ﹤0.01% | 486 |
|
|
2024
Q1 | $2.42M | Sell |
5,780
-512
| -8% | -$216K | ﹤0.01% | 466 |
|
|
2023
Q4 | $2.56M | Buy |
6,292
+770
| +14% | +$284K | ﹤0.01% | 444 |
|
|
2023
Q3 | $1.92M | Buy |
5,522
+834
| +18% | +$292K | ﹤0.01% | 489 |
|
|
2023
Q2 | $1.65M | Sell |
4,688
-1,606
| -26% | -$541K | ﹤0.01% | 522 |
|
|
2023
Q1 | $1.98M | Sell |
6,294
-1,190
| -16% | -$357K | ﹤0.01% | 507 |
|
|
2022
Q4 | $2.16M | Sell |
7,484
-41,441
| -85% | -$12.6M | ﹤0.01% | 512 |
|
|
2022
Q3 | $14.2M | Buy |
48,925
+236
| +0.5% | +$67.9K | 0.03% | 318 |
|
|
2022
Q2 | $13.7M | Buy |
+48,689
| New | +$13M | 0.02% | 316 |
|
|
2021
Q4 | – | Sell |
-84,040
| Closed | -$16.3M | – | 865 |
|
|
2021
Q3 | $15.4M | Sell |
84,040
-57,165
| -40% | -$11.2M | 0.03% | 287 |
|
|
2021
Q2 | $27.4M | Buy |
141,205
+126,205
| +841% | +$26.4M | 0.05% | 229 |
|
|
2021
Q1 | $3.21M | Sell |
15,000
-35,300
| -70% | -$7.75M | 0.01% | 376 |
|
|
2020
Q4 | $11.7M | Sell |
50,300
-724,100
| -94% | -$166M | 0.03% | 272 |
|
|
2020
Q3 | $209M | Sell |
774,400
-290,200
| -27% | -$80.1M | 0.55% | 57 |
|
|
2020
Q2 | $304M | Buy |
1,064,600
+54,700
| +5% | +$14.8M | 0.91% | 26 |
|
|
2020
Q1 | $233M | Buy |
1,009,900
+333,900
| +49% | +$76.6M | 0.84% | 31 |
|
|
2019
Q4 | $147M | Buy |
676,000
+477,600
| +241% | +$96.7M | 0.45% | 64 |
|
|
2019
Q3 | $32.4M | Buy |
198,400
+164,200
| +480% | +$29M | 0.1% | 154 |
|
|
2019
Q2 | $6.12M | Sell |
34,200
-173,300
| -84% | -$30.3M | 0.02% | 278 |
|
|
2019
Q1 | $36.8M | Sell |
207,500
-492,100
| -70% | -$90.9M | 0.13% | 148 |
|
|
2018
Q4 | $114M | Sell |
699,600
-204,925
| -23% | -$35.5M | 0.45% | 59 |
|
|
2018
Q3 | $172M | Buy |
904,525
+708,025
| +360% | +$126M | 0.56% | 48 |
|
|
2018
Q2 | $32.6M | Sell |
196,500
-824,000
| -81% | -$128M | 0.11% | 151 |
|
|
2018
Q1 | $165M | Buy |
1,020,500
+39,400
| +4% | +$6.44M | 0.61% | 47 |
|
|
2017
Q4 | $145M | Buy |
981,100
+70,398
| +8% | +$10.4M | 0.47% | 57 |
|
|
2017
Q3 | $133M | Buy |
910,702
+383,402
| +73% | +$57.7M | 0.46% | 56 |
|
|
2017
Q2 | $66.6M | Buy |
+527,300
| New | +$63.5M | 0.3% | 77 |
|
|
2015
Q1 | – | Sell |
-668,900
| Closed | -$78.4M | – | 690 |
|
|
2014
Q4 | $78.4M | Buy |
668,900
+325,140
| +95% | +$36.6M | 0.24% | 101 |
|
|
2014
Q3 | $38.3M | Buy |
343,760
+202,960
| +144% | +$19.3M | 0.12% | 159 |
|
|
2014
Q2 | $13.3M | Buy |
+140,800
| New | +$9.87M | 0.04% | 265 |
|
|
2013
Q3 | – | Sell |
-50,900
| Closed | -$4.06M | – | 427 |
|
|
2013
Q2 | $4.06M | Buy |
+50,900
| New | +$3.75M | 0.02% | 289 |
|
Other funds holding VRTX
1832 Asset Management's VRTX Position: Q3 2024 in Review
1832 Asset Management sold out of Vertex Pharmaceuticals (VRTX) in Q3 2024, closing a stake of 4,630 shares — an estimated $2.17M sold.
1832 Asset Management first reported a position in VRTX in Q2 2013 and held it in 31 quarters. The position peaked at $304M in Q2 2020. 1,545 funds tracked by Wall St. Rank hold VRTX as of Q3 2024.
- 1832 Asset Management reported no remaining Vertex Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
- 1832 Asset Management sold 4,630 Vertex Pharmaceuticals shares in Q3 2024, an estimated $2.17M.
- 1832 Asset Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 31 quarters.
- 1832 Asset Management's Vertex Pharmaceuticals position peaked at $304M in Q2 2020.
- 1,545 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2024.
Based on 1832 Asset Management's 13F filing for Q3 2024, filed 13 Nov 2024.